KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2025)

Rigel Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $395000.0 for Q4 2025.

  • Quarterly results put Operating Leases at $395000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $395000.0 (changed N/A YoY), and the annual figure for FY2025 was $395000.0, changed.
  • Operating Leases for Q4 2025 was $395000.0 at Rigel Pharmaceuticals, down from $556000.0 in the prior quarter.
  • Over the last five years, Operating Leases for RIGL hit a ceiling of $17.2 million in Q1 2021 and a floor of $100000.0 in Q1 2024.
  • Median Operating Leases over the past 5 years was $759000.0 (2021), compared with a mean of $2.7 million.
  • Biggest five-year swings in Operating Leases: tumbled 96.07% in 2021 and later soared 764.0% in 2025.
  • Rigel Pharmaceuticals' Operating Leases stood at $759000.0 in 2021, then increased by 28.06% to $972000.0 in 2022, then crashed by 70.68% to $285000.0 in 2023, then tumbled by 64.91% to $100000.0 in 2024, then soared by 295.0% to $395000.0 in 2025.
  • The last three reported values for Operating Leases were $395000.0 (Q4 2025), $556000.0 (Q3 2025), and $714000.0 (Q2 2025) per Business Quant data.